COVID-19 Vaccine Booster Dose Willingness Among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study

Mohammad Shehab, Fatema Alrashed, Ahmad Alfadhli
doi: https://doi.org/10.1101/2022.07.18.22277757

Article usage

Article usage: July 2022 to July 2025

AbstractFullPdf
Jul 2022398859
Aug 2022156424
Sep 20228705
Oct 20225305
Nov 20224703
Dec 20222825
Jan 20232838
Feb 202327213
Mar 20232827
Apr 20232115
May 20231515
Jun 20231257
Jul 2023713
Aug 202317125
Sep 20231143
Oct 2023620
Nov 20231694
Dec 20231202
Jan 2024600
Feb 2024716
Mar 2024600
Apr 2024835
May 2024243
Jun 2024942
Jul 2024715
Aug 20241024
Sep 20241403
Oct 2024563
Nov 2024816
Dec 2024401
Jan 2025766
Feb 20256235
Mar 202525286
Apr 202516710
May 20251795
Jun 202520813
Jul 2025011
Back to top
Posted July 18, 2022.
Download PDF

Supplementary Material

Data/Code
Email
COVID-19 Vaccine Booster Dose Willingness Among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study
Mohammad Shehab, Fatema Alrashed, Ahmad Alfadhli
medRxiv 2022.07.18.22277757; doi: https://doi.org/10.1101/2022.07.18.22277757
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area